About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Boston | 17,836 Studies Near You | Clareo Health

Clinical Trials LocationsBoston

Clinical Trials in Boston

Discover 17,836 clinical trials near Boston, Massachusetts. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 4181-4200 of 17,836 trials

COMPLETEDPhase 2< 1 mile

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

NCT01734512

This is an open label study of everolimus in children with recurrent or progressive low-grade glioma.

Pediatric Recurrent Progressive Low-grade GliomasPediatric Progressive Low-grade Gliomas

University of California, San Francisco65 participantsStarted Dec 2012

Los Angeles, California, United States • Los Angeles, California, United States • Oakland, California, United States +15 more locations

Active Not Recruiting< 1 mile

OCS DCD Heart + CAP Continued Follow-Up

NCT05741723

The objective of this post-approval study is to evaluate long-term outcomes of patients enrolled in the OCS DCD Heart and OCS DCD Heart CAP studies.

Heart Transplant

TransMedics276 participantsStarted Nov 2019

La Jolla, California, United States • Palo Alto, California, United States • New Haven, Connecticut, United States +17 more locations

Find Trials by Condition in Boston

Breast Cancerin Boston Lung Cancerin Boston Prostate Cancerin Boston Colorectal Cancerin Boston Melanomain Boston Leukemiain Boston Lymphomain Boston Pancreatic Cancerin Boston Ovarian Cancerin Boston Brain Cancerin Boston Diabetesin Boston

Data from ClinicalTrials.govTerms

COMPLETEDPhase 2< 1 mile

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

NCT03499808

This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment. Monoclonal antibodies, such as isatuximab, may interfere with the ability of cancer cells to grow and spread.

Amorphous, Eosinophilic, and Acellular DepositConstipationDiarrhea+10 more

SWOG Cancer Research Network43 participantsStarted Jun 2018

Anchorage, Alaska, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +342 more locations

RECRUITING< 1 mile

A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab

NCT07003100

This study is being done to assess mogamulizumab-associated rash in patients diagnosed with mycosis fungoides or sezary syndrome and treated with standard of care mogamulizumab. One of the most common side effects of mogamulizumab is a rash, currently named mogamulizumab-associated rash (MAR) which can look like MF or SS. However, mogamulizumab-associated rash (MAR) does not indicate failure of mogamulizumab, and may be a sign that the drug is working. If not properly evaluated, mogamulizumab-associated rash (MAR) could be misinterpreted as worsening of mycosis fungoides/sezary syndrome, which could lead doctors to recommend stopping mogamulizumab treatment early. The information learned by doing this research study may help tell the difference between mogamulizumab-associated rash (MAR) (sometimes also called "drug eruption") and worsening of the disease. It may also help to uncover information about the cause of mogamulizumab-associated rash (MAR).

Recurrent Mycosis FungoidesRecurrent Sezary SyndromeRefractory Mycosis Fungoides+6 more

City of Hope Medical Center100 participantsStarted Dec 2024

Duarte, California, United States • Palo Alto, California, United States • Tampa, Florida, United States +7 more locations

TERMINATEDPhase 3< 1 mile

Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis

NCT05132569

This was a multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tolebrutinib compared with placebo in adult participants aged 18 to 85 years old with moderate-to-severe generalized myasthenia gravis (gMG), who received Standard of Care (SoC). The double-blind (DB) treatment period of 26 weeks comprised of 7 site visits followed by a 2-year open label extension (OLE) period with quarterly visits. The efficacy of tolebrutinib versus placebo during the DB period was assessed by clinical evaluations, including scales based on physician examination or direct participant feedback i.e., patient reported outcomes (PROs). These evaluations continued during the OLE to measure long term efficacy and safety.

Myasthenia Gravis

Sanofi6 participantsStarted Dec 2021

Washington D.C., District of Columbia, United States • Boca Raton, Florida, United States • Tampa, Florida, United States +19 more locations

Active Not RecruitingPhase 2/3< 1 mile

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

NCT03470922

The purpose of this study is to determine whether relatlimab in combination with nivolumab is more effective than nivolumab monotherapy in treating unresectable melanoma or melanoma that has spread.

Bristol-Myers Squibb714 participantsStarted Apr 2018

Tucson, Arizona, United States • Los Angeles, California, United States • San Luis Obispo, California, United States +124 more locations

RECRUITINGPhase 1/2< 1 mile

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

NCT04150497

This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate the safety and clinical activity of UCART22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

B-cell Acute Lymphoblastic Leukemia

Cellectis S.A.52 participantsStarted Oct 2019

Los Angeles, California, United States • Aurora, Colorado, United States • Denver, Colorado, United States +16 more locations

Active Not RecruitingPhase 3< 1 mile

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

NCT04379570

This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.

Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+6 more

Alliance for Clinical Trials in Oncology1,167 participantsStarted Feb 2021

Birmingham, Alabama, United States • Fairbanks, Alaska, United States • Gilbert, Arizona, United States +523 more locations

Active Not RecruitingPhase 2< 1 mile

Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

NCT02257528

This phase II trial studies the side effects and how well nivolumab works in treating patients with cervical cancer that has grown, come back, or spread to other places in the body. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells.

Cervical AdenocarcinomaCervical Adenosquamous CarcinomaRecurrent Cervical Carcinoma+3 more

National Cancer Institute (NCI)26 participantsStarted May 2015

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +330 more locations

COMPLETEDNA41 miles

Combined TMS and Brief Cognitive Behavioral Therapy to Reduce Suicide

NCT03952468

High rates of Veteran suicide remain a tragedy. Rates of Veteran suicide have not decreased for 10 years, despite the best efforts of the field. Those interventions that do exist have only modest effects, which are simply insufficient for the magnitude of the problem. This proposal will combine two treatments - brief cognitive behavioral therapy (BCBT) and repetitive transcranial magnetic stimulation (TMS). Both of these interventions can reduce suicide and are available at Veterans Affairs Medical Centers across the country, yet to date no one has combined these therapies. This proposal will test the effect of this combination, and, if successful, will lead to a novel yet implementable new treatment to reduce Veteran suicide.

VA Office of Research and Development55 participantsStarted Nov 2019

Providence, Rhode Island, United States

Active Not RecruitingNA41 miles

Mindfulness & Mechanisms Study

NCT04626245

Hypertensive disorders of pregnancy (HDP) are the most common medical condition affecting pregnancy and a leading cause of maternal morbidity and mortality in the Unites States. HDP also increase lifetime cardiac disease risk in women and infants. Current interventions to prevent HDP are limited, and interventions that do not include medications are minimally effective at preventing HDP. Mindfulness interventions hold promise as a intervention to prevent HDP that does not require pregnant women to take medications. Past research shows that mindfulness interventions reduce blood pressure in adults with hypertension and pre-hypertension. However, past studies of mindfulness interventions for pregnant women have not allowed women at risk for HDP to participate. The preliminary study of prenatal mindfulness training for women at risk for HDP demonstrated benefit on maternal blood pressure and fetal growth. However, the mechanisms explaining effects of prenatal mindfulness training on risk for HDP are unknown. Building upon these promising preliminary findings, the proposed clinical trial will measure daily experiences of stress, physiological reactivity to stress, and interpersonal processes before and after prenatal mindfulness training. The investigators hypothesize that mindfulness training will impact these processes, which may lead to improved maternal cardiovascular parameters and reduced risk for HDP. N=150 pregnant women at risk for HDP will be randomized to an 8-week phone-delivered mindfulness intervention or usual care. For every participant, we will measure maternal cardiovascular parameters (24-hour blood pressure and uterine artery resistance values by ultrasound Doppler) before and after the 8-week period. All participants will complete surveys of daily experiences for 2 weeks before and after the 8-week period to evaluate mechanisms of mindfulness training on maternal cardiovascular parameters. Daily experiences will be measured using surveys delivered via smartphone-app, ambient audio sampling, and wearable wrist-worn biosensor monitoring (heart rate and heart rate variability).

Hypertension in Pregnancy

Lifespan150 participantsStarted Jun 2022

Providence, Rhode Island, United States

Active Not RecruitingPhase 346 miles

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

NCT05748600

The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma to evaluate improvements in lung function, asthma control, and quality of life. In addition, the study will further evaluate the safety and tolerability of dexpramipexole in participants with eosinophilic asthma.

Eosinophilic AsthmaAsthma; EosinophilicAsthma Attack

Areteia Therapeutics600 participantsStarted Jan 2023

Chandler, Arizona, United States • Peoria, Arizona, United States • Surprise, Arizona, United States +332 more locations

Active Not RecruitingPhase 378 miles

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

NCT00978458

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective when given together with or without temozolomide in treating patients with low-grade glioma. PURPOSE: This randomized phase III trial is studying radiation therapy so see how well it works when given together with or without temozolomide in treating patients with low-grade glioma.

Brain and Central Nervous System TumorsNeurotoxicity

Eastern Cooperative Oncology Group540 participantsStarted Nov 2009

Birmingham, Alabama, United States • Phoenix, Arizona, United States • La Jolla, California, United States +165 more locations

TERMINATEDPhase 4116 miles

Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment

NCT05552859

The TRENT trial is designed to confirm the efficacy and safety of Gla-300 compared with IDeg-100 in insulin-naïve patient (participants who have not tried insulin) with Type 2 Diabetes Mellitus (T2DM) and renal impairment. It will test the hypothesis that Gla-300 is non-inferior to IDeg-100 with glucose control. If achieved, the trial will also test for the superiority of Gla-300 compared with IDeg-100 in Hemoglobin A1c (HbA1c) reduction, without an increased potential risk of hypoglycemia.

Type 2 Diabetes MellitusRenal Impairment

Sanofi62 participantsStarted Dec 2022

Yuma, Arizona, United States • Buena Park, California, United States • Canyon Country, California, United States +65 more locations

TERMINATEDPhase 3249 miles

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years

NCT05513391

The purpose of this study was to demonstrate the non-inferior HAI immune response of quadrivalent recombinant influenza vaccine (RIV4) vs licensed Egg-Based Quadrivalent Influenza Vaccine (IIV4) for the 4 strains based on the egg-derived antigen in all participants aged 3 to 8 years and to describe the immunogenicity and safety profile of RIV4 compared to IIV4 in participants aged 3 to 8 years.

Influenza Immunization

Sanofi Pasteur, a Sanofi Company366 participantsStarted Nov 2022

Birmingham, Alabama, United States • Jonesboro, Arkansas, United States • San Diego, California, United States +28 more locations

COMPLETEDPhase 2368 miles

Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants

NCT04398706

Primary objectives: * To assess the safety profile of each SP0202 formulation and Prevnar 13 in toddlers and infants (after each and any injection). * To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of one dose in toddlers (Groups 1-4) * To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of 3 doses in infants (Groups 5-8) * To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after administration of a 4-dose schedule in infants (Groups 5-8) Secondary objectives: * To assess the immune response (serotype specific OPA titer) of the SP0202 formulations and Prevnar 13 1 month after the administration of one dose in toddlers (Groups 1-4) * To assess the immune response (serotype specific OPA titer) of the SP0202 formulations and Prevnar 13 1 month after the administration of 3 doses in a subset of infants (Groups 5-8) * To assess the immune response (serotype specific OPA titer) of the SP0202 formulations and Prevnar 13 1 month after administration of a 4-dose schedule in a subset of infants (Groups 5-8) * In toddlers: to describe the Ab responses against Pentacel antigens before and 1 month following injection of Pentacel * In infants: to describe the Ab responses against antigens of the routine pediatric vaccines (Pentacel, RotaTeq, ENGERIX-B, M-M-RII, and VARIVAX) when administered concomitantly with either SP0202 or Prevnar 13 (at pre-Dose 1 (as applicable) for RotaTeq, Diphteria, Tetanus and Pertussis antigens; at PD3 for ENGERIX-B, RotaTeq, and Pentacel; at PD4 for M-M-RII and VARIVAX\])

Pneumococcal ImmunisationDiphtheria ImmunisationTetanus Immunisation+8 more

Sanofi Pasteur, a Sanofi Company852 participantsStarted May 2020

Jonesboro, Arkansas, United States • Bellflower, California, United States • Huntington Park, California, United States +54 more locations

Active Not Recruiting407 miles

Burden of Recreational Water Illness Due to Exposure to Cyanobacteria and Their Toxins in Freshwater Beaches in Canada

NCT06579170

Swimming and other recreational water activities at public beaches are increasingly popular leisure activities among Canadians. However, harmful algal blooms caused by blue-green algae (i.e., cyanobacteria) have also been increasing reported at Canadian public beaches in recent years. These algal blooms can cause various acute illnesses among recreational water users through ingestion, inhalation of aerosols, or skin contact with contaminated water. In addition, blue-green algae blooms and their toxins can cause illnesses in pets and wildlife. Currently, baseline data are lacking on the risk of recreational water illness from exposure to blue-green algae blooms in Canada. This study will identify the burden of recreational water illness among recreational water users at four targeted beach sites in Ontario, Manitoba and Nova Scotia, over a two-year period. A prospective cohort study design will be used. The investigators will determine the risk of acquiring acute illness outcomes in recreational water users, as well as their pet dogs, that engage in different levels of water contact at beaches at risk of blue-green algae blooms. The investigators will examine differences in illness risks by gender, age, and location. Relationships between cyanobacterial cell counts, toxin levels, and environmental conditions with the risk of acute illness among participants will be determined. Overall, results will provide important data on the risk of recreational water illness from exposure to blue-green algae and their toxins in Canadian beach settings.

GastroenteritisGastrointestinal DiseasesEye Infections+3 more

Toronto Metropolitan University2,500 participantsStarted Jun 2024

Winnipeg, Manitoba, Canada • Halifax, Nova Scotia, Canada • Port Perry, Ontario, Canada +1 more locations

COMPLETEDPhase 1/2474 miles

Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

NCT04491877

The primary objectives of the study were: * To assess the safety profile of each dose of the study product after each and any administration in all infants and toddlers regardless of baseline serostatus. * To characterize the Respiratory Syncytial Virus (RSV) A serum neutralizing antibody responses to the study product in each vaccine group after vaccination in RSV-naïve participants. The secondary objectives of the study were: * To quantify the amount of vaccine virus shed by each participant by baseline serostatus. * To determine the proportion of vaccinated infants and toddlers in each vaccine group infected with the vaccine virus at D56 (56 days after vaccination 1) for Cohorts 1, 2, 3 and 4, and at Day 84 (28 days after vaccination 2) for Cohorts 2 and 4 by baseline serostatus. * To characterize the RSV A serum neutralizing antibody responses to the study product in each vaccine group after vaccination in RSV-experienced participants. * To characterize serum RSV anti-F immunoglobulin G (IgG) antibody responses to the study product in each vaccine group after vaccination by baseline serostatus. * To characterize serum RSV antibody responses (RSV A-neutralizing and anti-RSV F IgG) to the study product in each vaccine group after the RSV surveillance season or at least 5 months after the last vaccine administration by baseline serostatus.

Respiratory Syncytial Virus Infection

Sanofi Pasteur, a Sanofi Company259 participantsStarted Sep 2020

Gardena, California, United States • La Mesa, California, United States • Los Angeles, California, United States +26 more locations

COMPLETEDPhase 22277 miles

Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

NCT04646005

The primary objective of the study is to estimate the clinical benefit of cemiplimab + ISA101b after progression on first line chemotherapy, as assessed by objective response rate (ORR). The secondary objectives of the study are: * To characterize the safety profile of cemiplimab + ISA101b * To assess preliminary efficacy of cemiplimab + ISA101b as measured by duration of response (DOR), progression-free survival (PFS), and overall survival (OS)

Cervical Cancer

Regeneron Pharmaceuticals113 participantsStarted Jun 2021

Tucson, Arizona, United States • Tucson, Arizona, United States • Orange, California, United States +23 more locations

RECRUITING3437 miles

Skin Reactions Related to Thoracic Implantable Chamber Dressings

NCT07158879

Prospective, multicenter cohort of 500 patients newly treated with systemic chemotherapy with CCI. The main objective of this study is to measure the incidence of skin reactions related to thoracic implantable chamber dressings.

Institut Curie500 participantsStarted Jun 2025

Paris, France • Pirae, French Polynesia • Uturoa, French Polynesia

PreviousPage 210 of 892Next

Heart Diseasein Boston